Brainstorm Cell Therapeutics
(OTC) BCLI
Brainstorm Cell Therapeutics Financials at a Glance
Market Cap
$11.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$9.57M
EPS (TTM)
-$0.94
P/E Ratio
-1.15
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$1.00
Volume
21,868
Open
$1.01
Price
$1.00
Volume
21,868
Open
$1.01
Previous Close
$1.08
Daily Range
$1.00 - $1.06
52-Week Range
$0.46 - $1.69
Estimated Earnings Date
Aug 17, 2026
Dividend
$0.00
Beta (Volatility)
0.00 (Low)
Price
$1.00
Volume
21,868
Open
$1.01
Previous Close
$1.08
Daily Range
$1.00 - $1.06
52-Week Range
$0.46 - $1.69
Estimated Earnings Date
Aug 17, 2026
BCLI News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Brainstorm Cell Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
19
CEO
Chaim Lebovits
Website
www.brainstorm-cell.comHeadquarters
New York City, NY 10019, US
BCLI Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
109.21%
Return on Capital
N/A
Return on Assets
-1676.01%
Earnings Yield
-86.96%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$11.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
11.03M
Volume
21.87K
Avg. Volume
17.03K
Financials (TTM)
Gross Profit
-$85.00K
Operating Income
-$8.91M
EBITDA
-$8.73M
Operating Cash Flow
-$6.66M
Capital Expenditure
$0.00
Free Cash Flow
-$6.66M
Cash & ST Invst.
$15.00K
Total Debt
$1.49M
Brainstorm Cell Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$37.00K
+28.8%
Gross Margin
0.00%
N/A
Market Cap
$11.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$595.88K
N/A
Employees
20
N/A
Net Income
-$2.13M
+25.7%
EBITDA
-$2.01M
+33.8%
Quarterly Fundamentals
Total Cash
$15.00K
-99.1%
Total Debt
$1.49M
-15.9%
Accounts Receivable
$122.00K
+82.1%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$1.49M
-9.4%
Return on Assets
-16.76%
N/A
Return on Invested Capital
79.60%
N/A
Free Cash Flow
-$1.32M
+19.1%
Operating Cash Flow
-$1.32M
+19.1%